Clearside Biomedical (CLSD)
(Delayed Data from NSDQ)
$3.76 USD
-0.13 (-3.34%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.81 +0.05 (1.33%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLSD 3.76 -0.13(-3.34%)
Will CLSD be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLSD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLSD
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Beats Revenue Estimates
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
CLSD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Other News for CLSD
Is CLSD about to break its pattern? NR7 shows up after sliding 3.34%
Is CLSD positioned for a breakdown? Slingshot Bearish shows up after soaring 7.76%
Is CLSD ready to move lower? New 52 Week Low shows up after gaining 1.12%
CLSD makes New 52 Week Closing Low on September 16
CLSD makes New 52 Week Closing Low on September 15